1
|
Sun Z, Wang H, Xu Y, Liu Y, Wang L, Zhou R, Zhou R, Ma W, Zhang T. High expression of NXPH4 correlates with poor prognosis, metabolic reprogramming, and immune infiltration in colon adenocarcinoma. J Gastrointest Oncol 2024; 15:641-667. [PMID: 38756632 PMCID: PMC11094489 DOI: 10.21037/jgo-23-956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Accepted: 03/15/2024] [Indexed: 05/18/2024] Open
Abstract
Background Colon adenocarcinoma (COAD) is a prevalent gastrointestinal malignant disease with high mortality rate, and identification of novel prognostic biomarkers and therapeutic targets is urgently needed. Although neurexophilin 4 (NXPH4) has been investigated in several tumors, its role in COAD remains unclear. The aim of this study was to explore the prognostic value and potential functions of NXPH4 in COAD. Methods The expression of NXPH4 in COAD were analyzed using The Cancer Genome Atlas (TCGA) and datasets from the Gene Expression Omnibus (GEO) database. The prognostic value of NXPH4 was determined using Kaplan-Meier analysis and Cox regression analysis. To investigate the possible mechanism underlying the role of NXPH4 in COAD, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) were employed. The correlation between NXPH4 expression and immune cell infiltration levels was examined thorough single-sample gene set enrichment analysis (ssGSEA). Furthermore, the competing endogenous RNA (ceRNA) regulatory network that may be involved in NXPH4 in COAD was predicted and constructed through a variety of databases. Results NXPH4 expression was significantly higher in COAD tissue compared with normal colon tissues. Meanwhile, high expression of NXPH4 was associated with poor prognosis in COAD patients. GO-KEGG and GSEA analyses indicated that NXPH4 was associated with glycolysis and hypoxia pathway, and may promote COAD progression and metastasis by modulating metabolic reprogramming. ssGSEA analysis demonstrated that NXPH4 expression also associated with immune infiltration. Furthermore, we identified various microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) as upstream regulators of NXPH4 in COAD. Conclusions The present study revealed that high expression of NXPH4 is associated with tumor progression, metabolic reprogramming, and immune infiltration. These findings suggest that NXPH4 could serve as a reliable prognostic biomarker and a promising therapeutic target in COAD.
Collapse
Affiliation(s)
- Zhe Sun
- College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
| | - Haodi Wang
- College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
| | - Yao Xu
- Institute of Biology and Medicine, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, China
| | - Yichi Liu
- College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
| | - Lu Wang
- College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
| | - Ruijie Zhou
- Institute of Biology and Medicine, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, China
| | - Runlong Zhou
- Institute of Biology and Medicine, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, China
| | - Wenjian Ma
- College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
- Qilu Institute of Technology, Jinan, China
| | - Tongcun Zhang
- College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
- Institute of Biology and Medicine, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, China
| |
Collapse
|
2
|
Brown DV, Anttila CJA, Ling L, Grave P, Baldwin TM, Munnings R, Farchione AJ, Bryant VL, Dunstone A, Biben C, Taoudi S, Weber TS, Naik SH, Hadla A, Barker HE, Vandenberg CJ, Dall G, Scott CL, Moore Z, Whittle JR, Freytag S, Best SA, Papenfuss AT, Olechnowicz SWZ, MacRaild SE, Wilcox S, Hickey PF, Amann-Zalcenstein D, Bowden R. A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq. Genomics 2024; 116:110793. [PMID: 38220132 DOI: 10.1016/j.ygeno.2024.110793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 11/29/2023] [Accepted: 01/09/2024] [Indexed: 01/16/2024]
Abstract
Single-cell RNA sequencing (scRNA-Seq) has emerged as a powerful tool for understanding cellular heterogeneity and function. However the choice of sample multiplexing reagents can impact data quality and experimental outcomes. In this study, we compared various multiplexing reagents, including MULTI-Seq, Hashtag antibody, and CellPlex, across diverse sample types such as human peripheral blood mononuclear cells (PBMCs), mouse embryonic brain and patient-derived xenografts (PDXs). We found that all multiplexing reagents worked well in cell types robust to ex vivo manipulation but suffered from signal-to-noise issues in more delicate sample types. We compared multiple demultiplexing algorithms which differed in performance depending on data quality. We find that minor improvements to laboratory workflows such as titration and rapid processing are critical to optimal performance. We also compared the performance of fixed scRNA-Seq kits and highlight the advantages of the Parse Biosciences kit for fragile samples. Highly multiplexed scRNA-Seq experiments require more sequencing resources, therefore we evaluated CRISPR-based destruction of non-informative genes to enhance sequencing value. Our comprehensive analysis provides insights into the selection of appropriate sample multiplexing reagents and protocols for scRNA-Seq experiments, facilitating more accurate and cost-effective studies.
Collapse
Affiliation(s)
- Daniel V Brown
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia.
| | - Casey J A Anttila
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia
| | - Ling Ling
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia
| | - Patrick Grave
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia
| | - Tracey M Baldwin
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia
| | - Ryan Munnings
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Anthony J Farchione
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Vanessa L Bryant
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia; The Royal Melbourne Hospital, 300 Grattan St, Parkville, Melbourne 3010, VIC, Australia
| | - Amelia Dunstone
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia
| | - Christine Biben
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Samir Taoudi
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Tom S Weber
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Shalin H Naik
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Anthony Hadla
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Holly E Barker
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Cassandra J Vandenberg
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Genevieve Dall
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Clare L Scott
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Zachery Moore
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - James R Whittle
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia; Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne 3010, VIC, Australia
| | - Saskia Freytag
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Sarah A Best
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Anthony T Papenfuss
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia; Peter MacCallum Cancer Centre, 305 Grattan St, Parkville, Melbourne 3010, VIC, Australia
| | - Sam W Z Olechnowicz
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Sarah E MacRaild
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia
| | - Stephen Wilcox
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia
| | - Peter F Hickey
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Daniela Amann-Zalcenstein
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia
| | - Rory Bowden
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade VIC, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, Melbourne 3010, VIC, Australia.
| |
Collapse
|
3
|
Alkhathami AG, Hadi A, Alfaifi M, Alshahrani MY, Verma AK, Beg MMA. Serum-Based lncRNA ANRIL, TUG1, UCA1, and HIT Expressions in Breast Cancer Patients. DISEASE MARKERS 2022; 2022:9997212. [PMID: 35132340 PMCID: PMC8817891 DOI: 10.1155/2022/9997212] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Revised: 09/25/2021] [Accepted: 01/07/2022] [Indexed: 12/14/2022]
Abstract
Breast cancer is a heterogeneous disease and is the most common and prevalent form of malignancy diagnosed in women. lncRNAs are found to be frequently dysregulated in cancer, and its expression plays a critical role in tumorigenesis. The study included 100 histopathologically confirmed, newly diagnosed untreated patients of invasive ductal carcinoma (IDC) of breast cancer patients and 100 healthy subjects. After blood collection, the serum was separated and total RNA was extracted, cDNA was synthesized using 100 ng of total RNA, and lncRNA (ANRIL, TUG1, UCA1, and HIT) expression was analyzed. Increased ANRIL (3.83-fold), TUG1 (7.64-fold), UCA1 (7.82-fold), and HIT (3.31-fold) expressions were observed in breast cancer patients compared to healthy controls. Relative expression of lncRNAs UCA-1 (p = 0.010) and HIT-1 (p < 0.0001) was significantly elevated in patients with advanced breast cancer stage compared to those with early-stage disease. While lncRNA TUG-1 expression was found to be higher in patients with early-stage tumors than those with advanced-stage tumors (p = 0.06), lncRNA ANRIL showed increased expression in patients with PR positive status (p = 0.04). However, we found a significant difference in lncRNA HIT expression in HER-2 positive breast cancer patients compared to HER-2 negative breast cancer patients (p = 0.005). An increase in the expression of serum lncRNAs ANRIL (p < 0.0001), UCA-1 (p = 0.004), and HIT (p < 0.0001) was observed in the distant organ metastatic breast cancer patients. In the ROC curve concerning lymph node involvement, the sensitivity and specificity of lncRNA HIT were 68% and 58%, respectively (p value = 0.007). In the ROC curve w.r.t. stages of disease, the sensitivity and specificity of lncRNA HIT were 80% and 50%, respectively (p value < 0.0001). Better sensitivity and specificity were observed for lncRNA HIT (sensitivity 91% and specificity 78%; p value < 0.0001) and ANRIL (sensitivity 70% and specificity 60%; p value < 0.0001) w.r.t distant organ metastases.
Collapse
Affiliation(s)
- Ali G. Alkhathami
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 61413, Abha 9088, Saudi Arabia
| | - Abdul Hadi
- Department of Medicine, Xi'an Jiaotong University, China
| | - Mohammed Alfaifi
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 61413, Abha 9088, Saudi Arabia
| | - Mohammad Yahya Alshahrani
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 61413, Abha 9088, Saudi Arabia
| | - Amit Kumar Verma
- Department of Zoology and Environmental Sciences, GKV, Haridwar, India
| | - Mirza Masroor Ali Beg
- Faculty of Medicine, Alatoo International University, Bishkek, Kyrgyzstan
- Centre for Promotion of Medical Research, Alatoo International University, Bishkek, Kyrgyzstan
| |
Collapse
|